Intelligence Feed event · Equity · 2026-09-19

    Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery

    Question

    Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery

    Direct answer

    Twist Bioscience established an agreement with Eli Lilly to provide antibody characterization services using its AbLab model within Lilly's TuneLab AI-powered discovery program. The commercial structure pairs Twist's synthetic DNA and antibody library generation with Lilly's therapeutic pipeline, expanding computational biopharma service demand.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/twist-bioscience-partners-with-eli-lilly-on-tunelab-ai-drug-discovery-e5db48

    EQUITY
    Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery
    Twist Bioscience established an agreement with Eli Lilly to provide antibody characterization services using its AbLab model within Lilly's TuneLab AI-powered discovery program. The commercial structure pairs Twist's synthetic DNA and antibody library generation with Lilly's therapeutic pipeline, expanding computational biopharma service demand.
    TWSTLLY
    Impact
    70
    SEP 19
    SIG
    85%
    TWSTLLY
    Twist Bioscience Partners With Eli Lilly on TuneLab AI Drug Discovery
    Twist Bioscience established an agreement with Eli Lilly to provide antibody characterization services using its AbLab model within Lilly's TuneLab AI-powered discovery program. The commercial structure pairs Twist's synthetic DNA and antibody library generation with Lilly's therapeutic pipeline, expanding computational biopharma service demand.
    → High-throughput synthetic biology service revenues expand TWST gross margins via enterprise pharma AI discovery commitments from LLY.
    Impact
    Twist Bioscience established an agreement with Eli Lilly to provide antibody characterization services using its AbLab model within Lilly's TuneLab AI-powered discovery program. The commercial structure pairs Twist's synthetic DNA and antibody library generation with Lilly's therapeutic pipeline, expanding computational biopharma service demand.
    Affected
    TWSTLLY
    Transmission
    High-throughput synthetic biology service revenues expand TWST gross margins via enterprise pharma AI discovery commitments from LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TWSTbiopharma service revenue growth and enterprise AI validationUp1-4wTwist partners with Eli Lilly to supply antibody characterization on Lilly TuneLab.
    LLYpipeline efficiency gains in preclinical AI antibody screeningUp1-3mEli Lilly integrates Twist AbLab data into its TuneLab drug discovery platform.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month